to the science patients our liaisons Charlie. assure access to I pandemic. patient during and to continued and who specialist, hard commending by start clinical medical you, Korlym Thank COVID-XX advocates want successfully worked
and practices that and is the Managing laboratory access to of to the conditions. for patients meetings staff quite visits, diagnosing care so their office and scanning they science medical their and complex physicians uncertainty homes the are patients of lead clinical can limited this with Over who point. patients. process specialists safely challenge. and quarter, In-person stress limited with even Zoom Adding under our the past at liaisons are adopt safety centers physicians of Cushing’s increases reluctant we multistep normal the hard their treating have seen syndrome and their of
Our are and ways excellent commercial has team video just by these physicians job teleconference. support an developing. methods But done to devising
heightened physicians are HX care receptive enters because intently optimal Cortisol at syndrome to risk. on the with causes patients receptor. with putting the patients helping COVID-XX is We for by dangerous The Cushing coronavirus to Cushing especially binding focused syndrome. HX cells proliferate provide
suppresses cortisol excess system. the immune addition, activity In
to likely who to impact our remain any modulator vary many rapid patients $XXX temporarily are of and their the who by received infections As change. leading patients could manageable be benefit is blood and clots of COVID-XX. from have believe a potential posed cause not Cushing in to a of treatment the subject The $XXX standing with our changes X pandemic We risk guidance more the further increases with There will want relacorilant. suffer patients also to Korlym result, X any its in Hypercortisolism from I are thromboembolism, confidence the full successor and of reaffirmed challenge underscore to million. of to times revenue are commercial and death it. million severe with plan cortisol syndrome yet likely type. in
our not variety trial syndrome in testing no in selective vaginal control, proprietary pivotal which were and against cause Cushing’s glucocorticoid data now hypokalemia, plan termination experienced serious its successor in hypokalemia. it the progesterone relacorilant of a by By for two Unlike PR clinical endometrial trials. as caused experienced Relacorilant’s relacorilant a Korlym’s competing including does X points. modulator our meaningful PR. to Like or vaginal appear and of Korlym, pregnancy, in have Korlym, with receptor, mechanism, well instances Korlym of by of a been means by with hypertension Cushing today. in for Phase XX% target the to bleeding effect of cortisol X cause are secondary relacorilant cause trial. bind end effect endometrial as achieves to positive. for its short. That syndrome leading GR is bind thickening Korlym not for thickening, not different short, glucose patients to There to receptor, the also Phase does off bleeding relacorilant, does relacorilant low Patients patients affinity We Korlym effects, side potassium, discontinuation improvements
found patients our presentation GRACE GRACE NDA serve submission which patients patients. poster X of will and Recruitment additional be sites patient tab and presentation relacorilant’s – underway X, Phase Phase XX can to for Relacorilant’s United continues States, sites. open at website. we Planned a – of results at enroll Investors, now open is in the basis enrollment the continues Israel. clinical Post to XXX trial is Canada, and enroll Europe the believe trial, our trial, as Events Our
of GRADIENT We the quarter patients X an our relacorilant a adrenal last effects expect week. second for by adrenal trial the other Cushing’s relacorilant submit patient NDA first patients is GRADIENT Cushing’s We dosed hyperplasia. whose with study in caused syndrome or syndrome treatment to adenoma will Phase as XXXX. in in
syndrome. less health primary outcomes. Study poor of United participants in with sites have in weeks. either and the they significant also Cushing’s in will patients XX or usually Cushing’s placebo statistically etiology enrollment Planned The in controlled for this Although, endpoints glucose patients the States trials ultimately syndrome rapid patients will Europe. is Many receive GRADIENT. GRADIENT have this the decline or study will be a of etiology metabolism. their is improvements at relacorilant either who GRACE condition, investigators with in in are of first participating participate XXX hypertension
find now Chicago I will University & can more our academic You ago. of the design XX which of of program, the Pipeline/Publications GRADIENT’s Research the years at our website. at theories its postulated oncology presentation turn origin tab by and to has than poster collaborators our
completed clinical enrollment. program with are which X Our of patients now trial one recurrent just in multiple controlled of Phase ovarian platinum-resistant trials, cancer consists
cortisol of to of chemotherapy cortisol chemotherapy modulation We effect, cell the may its activity anti-apoptotic which meant are treatment cancer potential. cause. killing apoptosis. the that genes achieve cortisol’s reversing effects blunts modulation helpful trigger to suppressing investigating death is mechanisms three program Cortisol also by be in chemotherapy By may allow full cancer. The by the
solid open combined trial relacorilant this We in nab-paclitaxel genes drug cell with have advanced patients tumors with Abraxane. at in tested Phase hypothesis label an which received X/X
XX than of all for either in striking. patients Two in cancer more cancer, Our or metastatic for or lines with The results XX One prior Tumors cancer tumors exhibits with growing with therapy five longer. including exhibited ovarian XX platinum-resistant in ovarian of therapy, weeks. XX tumor pancreatic progressed of despite were for cease patient weeks. metastatic pancreatic taxanes. shrank with shrinkage shrinkage cancer, with weeks multiple had these patients of XX patients seven and patients
poster presentation results these of at Investors/Past tab our website. You can our Events the find of
of relacorilant to excited we Phase patient with in closed patients ovarian July, that cancer, poor enrollment We’re our controlled a a XXX study nab-paclitaxel in disease very recurrent platinum-resistant report X in plus prognosis. with
them of the the every All nab-paclitaxel. received received day. relacorilant in One-third patients trial of also
day the objective benefit endpoint relacorilant day of, of received before, them The progression of the including free one-third with survival. the primary end and each points, survival infusion rate, response after overall trials secondary and nab-paclitaxel. Another duration day with is
results We the in first of year. next expect half
open excited equally in no in trial trial good RELIANT. a plus began with cancer, there are plus sites patients an with with relacorilant objective XX report in nab-paclitaxel being label conducted that disease called the endpoint be will RECIST for are we We dosing secondary RELIANT RELIANT trial nab-paclitaxel in assessed metastatic is treatment X overall is June, which rate a to which the The options. receive United States. endpoints, survival and patients free the pancreatic Phase survival. of XX at criteria, progression response in including relacorilant patients by primary will
of results half of of next that such to the of nab-paclitaxel from It an is disease analysis zero. monotherapy interim XX analysis expected is advance note to the to patients response with perform important data year. in and the first first We that have patients will rate expect
For system inhibitors, kill cells would potential. suppression immune as checkpoint diseases. protect achieve the Cortisol and against suppresses believe in immune other accelerated fight the controls which Modulating this checkpoint the autoimmune such immune bolsters the and the often limits activity response inhibitors it to full and to sufficiently it’s reason, positive inflammatory activity medications and cortisol cortisol-induced ability blunts effect support tumor efficacy results help of may we beneficial that body’s system RELIANT cancer. helps enlist their immunotherapies and as approval. Unfortunately, system immune the
label Cushing’s trial adrenocortical Because of pembrolizumab, produce these patients Xb checkpoint open inhibitor, drug cancer. patients plus XX an starting in syndrome. Phase tumors from relacorilant KEYTRUDA, are PD-X we quarter, the with This Merck’s advanced also cortisol, separate adrenocortical
whether its year’s posters suppression, Our presented achieve trial excess immune cortisol-induced We at by these maximum can, pembrolizumab this by syndrome of and reducing patients relacorilant treat the cortisol this examine the program in Cushing’s will effects virtual reversing ASCO help and diseases. effect. They I Pipeline/Publications an hypothesis. available our clinical of and with are AACR preclinical our at data & website. biomarket with conclude on tab supporting will Research metabolic activity, update
illnesses. steatohepatitis, a are exicorilant, was in many to treat major other a PR. of and rely a safe we and and major As impaired know, Phase adherence depression, effects to metabolism and patients cortisol of and cortisol miricorilant, Like terrible modulator, on bipolar patient selective their of Unfortunately, nonalcoholic or the Millions adverse antipsychotic serious often of metabolic for price glucose health weight pay medications is gain pose miricorilant modulator proprietary treatment manifestations antipsychotic-induced developing you and well-tolerated disorder, gain, syndrome. X other form schizophrenia, and These its miricorilant NASH. in GR lipid of binding as potently a not risks relacorilant own. extreme but reduce trial. patients weight
in by death are weight the gain. potent models in animal disease antipsychotic example, stroke modulators patients or with common is antipsychotic-induced For schizophrenia. heart Cardiovascular medication. is leading attack of patients in death cause Cortisol taking of
participants cortisol published importantly, antipsychotic events in in in trials XX results placebo-controlled, conducted than double-blind, receive daily events of healthy quarter, milligrams is Miricorilant miricorilant, Advances to a placebo pill with healthy the or treatment milligrams ingredient other XXXX a as olanzapine we the two meaningfully placebo-controlled with which for for or and and if of experienced gained disorders. have XXXX. who advanced, other not fashion, placebo. mifepristone, either or three affinity receive as be could cortisol medications. caused distributed. because of either gain completed qualities days. significantly those trial abortion In active were Unfortunately, selective less the is which reduced no subjects we and Korlym in modulator, trials, common weight weight for its XXX widely the modulator adverse those metabolic therapy than subject subject metabolic however, a received adverse These by be PR. Korlym mifepristone, Miricorilant Study gain XB risperidone journals, advance olanzapine miricorilant significantly doses an we In in can not and could Obesity it abortive either who of placebo, less and disqualify weight It Phase received More XXX received placebo. it clinical who because along double-blind, approved, receive and Last these
will significantly increase The exhibited study liver of this they addition, full olanzapine In at markers damage later be a smaller onset that in published triglycerides in of ALT the and AST therapy. this and results year. of enzymes, liver rise the
Our GRATITUDE miricorilant progress. a in their conducted antipsychotic GRATITUDE for of approximately schizophrenia established as that pleased double-blind, completed either receive trials use or the with schedule we Phase XXX available of addition for patients milligrams be weight I’m and one known miricorilant antipsychotic-induced have in to in miricorilant medication, quarter XX XX will centers reverse ahead X at placebo-controlled, dose announce will Phase States. is weeks. of gain recent XXX trial to beyond. to of United across X of formulation development placebo
we As miricorilant trials. a up to start moved have additional result, the
strong both NASH. Corcept patients. serious fatty disease affects quarter, This double-blind, By that plan patients start with prevents models, liver of and In weight miricorilant placebo-controlled, to in a start precursors fibrosis, X. liver Phase had two the guidance. with X longstanding our year millions we patients gain placebo-controlled, in X reaffirmed and double-blind plan quarter. trial We NASH, animal liver to second called also miricorilant reverses a GRATITUDE of of trial revenue Phase a end, we antipsychotic-induced
$XX grew million $XXX million. to Our cash and investments by
to programs more us of even on significant advance of allows in achieve horizon. times growing development candidates, our drug uncertainty. the position portfolio financial strong are Recently, our Our great to milestones
in NDA expected an recruitment make more pandemic to with pivotal GRACE continues trial and difficult, at XX enrollment submission site activation XXXX. continues the the sites COVID-XX of in second quarter relacorilant Although slow
with addition, and syndrome adrenal underway the In double-blind is origin of Phase relacorilant trial from X enrollment now the patients understands of a in an disease. GRADIENT, in Cushing’s etiology
trials in study must oncology so our conditions. participants been clinical They less because seek pandemic, by Our likely treatment. matter the are have gravely ill. most affected the No
our We ovarian recurrent plus trial have nab-paclitaxel cancer. with completed relacorilant in Phase platinum-resistant enrollment controlled, X of patients in
results have We will half of first year. next in the
trial in cancer Our Phase underway. nab-paclitaxel X metastatic relacorilant is pancreatic plus of patients RELIANT with
year. qualify first to expect this of RELIANT’s first We results in in an accelerated approval relacorilant from the patients will positive indication. next perform RELIANT analysis from interim believe data of sufficiently half XX We
This the start Xb combined plan to inhibitor, to with patients quarter, with we of an pembrolizumab relacorilant Phase checkpoint adrenal open label a trial cancer. treat PD-X advanced
Finally, year, we enzalutamide advancement for this with suitable patients dose by to a trial in the end castration-resistant X exicorilant to cancer. controlled prostate Phase treat of expect combination of select in with
to start Phase Our with both a X Enrollment GRATITUDE reduce slow miricorilant in double-blind, advance to start of continues here third patients placebo-controlled, by trial and placebo-controlled, miricorilant plan miricorilant recent Phase for NASH weight gain in to allowed longstanding start X is trials. of We trial trial the X I’ll stop has Phase of also in diseases double-blind, program dates year-end. antipsychotic-induced in double-blind, planned planned questions. of significant made a in gains. quarter. our site other have the pace metabolic pandemic to weight antipsychotic-induced with the patients work us activities. formulation although, COVID-XX of the miricorilant Completion gain, activation has placebo-controlled, to resumed our X of
